Merck & Mayo Clinic Data Powerhouse 🔗

Merck (MSD outside the U.S. and Canada) and Mayo Clinic announced an R&D collaboration that integrates Mayo Clinic Platform architecture plus clinical/genomic and multimodal datasets into Merck’s AI-enabled discovery efforts, including virtual cell ambitions. The initial focus areas are IBD, atopic dermatitis, and multiple sclerosis.

Eli Lilly’s "AI Factory" 🔗

Eli Lilly and NVIDIA are launching an AI co-innovation lab to build an AI-native drug discovery engine focused on physical AI and robotics. The goal is to move beyond AI-assisted research toward automated, workflow-level discovery. The companies say they plan to invest up to $1 billion over five years in the initiative.

The "Prima" Breakthrough 🔗

University of Michigan researchers unveiled Prima, an AI-powered clinical decision support model that analyzes brain MRIs in seconds and helps differentiate across 50+ neurological diagnoses (reported as 92% overall accuracy, with even higher accuracy in complex cases).

The "Sovereign Content" Marketplace Shift 🔗

Microsoft has introduced its Publisher Content Marketplace (PCM), a new framework for licensed use of premium publisher content in AI products. In parallel, Admanager (powered by Doceree) has launched a healthcare-focused Licensed Content Marketplace aimed at giving medical publishers more control over how their content is accessed, attributed, and monetized in the AI economy.

The Signal: For life sciences, this is a massive regulatory and IP move. It allows publishers of high-compliance medical content to govern how their data is used to train AI models. This "missing layer" solves the attribution and monetization problem that has been holding back premium medical journals from fully entering the AI training economy.

DNA as the New "Natural Language" (IBM & DeepMind) 🔗

IBM Research and Google DeepMind have recently highlighted a paradigm shift in genomics. According to the latest February 2026 insights, biology is entering its "GPT era." New foundation models, such as AlphaGenome, are moving beyond treating DNA as a static data string and are instead "reading" it like a programming language with its own complex syntax and logic.

The Signal: This represents a pivot from descriptive analysis to generative design. The industry is shifting from asking "what does this gene do?" to "how can we write a sequence that triggers a specific function?" This opens the door to designing therapeutics directly within the "source code" of life.

The "Dark Genome" Opportunity: DeepMind's AlphaGenome (published in Nature) can process up to 1 million base pairs at once. This allows it to decode the "regulatory dark matter" of the genome—the 98% of DNA that doesn't code for proteins but controls their expression. For the market, this identifies a massive new wave of drug targets previously invisible to standard algorithms.

The "Agentic" R&D Pivot: From Pilots to Production 🔗

The industry has officially moved past the "chatbot" phase. A landmark Deloitte 2026 Outlook survey of biopharma executives found that 30% have now prioritized "Agentic AI"—systems that can autonomously act, make decisions, and execute multi-step research tasks—as a core strategic trend for this year.

The Signal: Deloitte reports that only 9% of life sciences leaders are seeing significant returns from AI efforts so far, which helps explain the shift from early experimentation toward more operational, outcome-driven applications, including agentic systems that can orchestrate multi-step workflows.

The "Clinical Accountability" Era 🔗

A new market intelligence report from Black Book Research that quantifies where healthcare capital is moving in 2026 shows that VCs are now "doubling down on AI that ships."

The Signal: Investment criteria have shifted from "visionary discovery" to "proven integration." In 2026, funding is moving toward AI tools that can integrate directly into clinical workflows, with 55% of investors now requiring "outcomes-grade real-world data" before engagement.

The Focus: Specifically seeking projects in Health and Life Sciences, Crisis Resilience, and Environmental Science.

The Perk: Beyond the funding, selected organizations get engineering support from Google’s top AI researchers and access to their technical infrastructure.

Deadline: Applications are open until April 17, 2026.

Link: Apply for the Google.org AI for Science Challenge